Search - tctmd.com

Displaying 21 - 40 of 113

Sort: Relevancy | Date

Presentation ESC 2022

Colchicine and Aspirin in Community Patients with COVID-19: An Open-label, Factorial, Randomized Trial

Presenter: John Eikelboom

August 29, 2022

Presentation ESC 2022

Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial

Presenter: Sanjit Jolly

August 28, 2022

Presentation TCT 2020

TICO-STEMI: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor With Aspirin in STEMI

Presenter: Byeong-Keuk Kim

October 14, 2020

Presentation ACC 2020

The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: COMPASS Diabetes

Presenter: Deepal L. Bhatt

March 30, 2020

Presentation ACC 2020

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Presenter: Yangsoo Jang

March 30, 2020

Presentation TCT 2019

Is it TWILIGHT for Aspirin? Critical Appraisal and Interpretation of the Trial

Presenter: Pascal Vranckx

September 28, 2019

Presentation TCT 2019

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Presenter: Amit Vora

September 28, 2019

Presentation TCT 2019

Aspirin Variability, Interactions and Impact of Different Formulations

Presenter: Dominick Angiolillo

September 28, 2019

Presentation TCT 2019

Evidence for Chronic Aspirin Use in CV Patients: COMPASS and More

Presenter: Sanjit Jolly

September 28, 2019

Presentation TCT 2019

Reducing Aspirin Use in ACS and PCI (With and Without AFib): How Good Is the Evidence?

Presenter: C. Michael Gibson

September 28, 2019

Presentation TCT 2019

Aspirin Use for Primary and Secondary Prevention: Critical Appraisal of What We Know and What We Don't

Presenter: Davide Capodanno

September 28, 2019

Presentation TCT 2019

TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

Presenter: Usman Baber

September 26, 2019

Presentation TCT 2019

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Presenter: Stephan Windecker

September 26, 2019

Presentation TCT 2019

Case Resolution: How Did I Treat and What Happened?

Presenter: Amit Vora

September 26, 2019

Presentation TCT 2019

The Approach to the High Bleeding Risk Patient: The Dos and the Don’ts!

Presenter: Bernard Chevalier

September 26, 2019

Presentation TCT 2019

Long-Term Antithrombotic Therapy After PCI: How Do I Incorporate COMPASS Into My Practice?

Presenter: Robert Welsh

September 26, 2019

Presentation TCT 2019

De-Escalation: When and How? — The Role of Platelet Function and Genetic Testing

Presenter: Francesco Franchi

September 26, 2019

Presentation TCT 2019

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor-Plus-Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

Presenter: Roxana Mehran

September 26, 2019

Presentation TCT 2019

Insights From SMART CHOICE

Presenter: Joo-Yong Hahn

September 26, 2019

Presentation TCT 2019

Insights From STOP DAPT-2

Presenter: Takeshi Kimura

September 26, 2019

Advertisement

Colchicine and Aspirin in Community Patients with COVID-19: An Open-label, Factorial, Randomized Trial

Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial

TICO-STEMI: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor With Aspirin in STEMI

The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: COMPASS Diabetes

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Is it TWILIGHT for Aspirin? Critical Appraisal and Interpretation of the Trial

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Aspirin Variability, Interactions and Impact of Different Formulations

Evidence for Chronic Aspirin Use in CV Patients: COMPASS and More

Reducing Aspirin Use in ACS and PCI (With and Without AFib): How Good Is the Evidence?

Aspirin Use for Primary and Secondary Prevention: Critical Appraisal of What We Know and What We Don't

TWILIGHT Thrombogenicity Substudy: Impact of Ticagrelor Alone vs. Ticagrelor Plus Aspirin on Ex-Vivo Blood Thrombogenicity in High-Risk Patients Undergoing PCI

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Case Resolution: How Did I Treat and What Happened?

The Approach to the High Bleeding Risk Patient: The Dos and the Don’ts!

Long-Term Antithrombotic Therapy After PCI: How Do I Incorporate COMPASS Into My Practice?

De-Escalation: When and How? — The Role of Platelet Function and Genetic Testing

TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy vs. Ticagrelor-Plus-Aspirin Beginning at 3 Months in High-Risk Patients Undergoing PCI

Insights From SMART CHOICE

Insights From STOP DAPT-2

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content